Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates

Omeros Corporation maintains a Buy rating, driven by Yartemlea's FDA approval for TA-TMA and the Novo Nordisk zaltenibart deal. OMER's 2025 net loss narrowed to $(3.35m) due to a $237.6m gain on zaltenibart rights; cash position improved and debt reduced by 47%. Yartemlea, priced at $36k per vial, targets a potential $5.4bn TAM with first-mover advantage, but faces potential pricing and competitive risks as Soliris generics emerge.